Press releases
* (R) = Regulatory press releases
Nov 30, 2023
(R) New number of shares and votes in Cantargia
Nov 24, 2023
Cantargia reports new preclinical data confirming the potential of nadunolimab and CAN10
Oct 26, 2023
Invitation to presentation of Cantargia’s report for the third quarter of 2023 on November 10 at 3.00 p.m. CET
Oct 16, 2023
Cantargia to present clinical phase Ib data on nadunolimab in triple-negative breast cancer at ESMO Congress 2023
Oct 4, 2023
(R) Cantargia: Third party appeals recent EPO decision to maintain granted Cantargia patent
Sep 18, 2023
(R) Cantargia announces new nadunolimab clinical trial in leukemia financed by external US grant
Sep 6, 2023
(R) Cantargia: FDA grants Orphan Drug Designation to CAN10 for treatment of systemic sclerosis
Aug 22, 2023
(R) Cantargia publishes half year report
Aug 14, 2023
Invitation to presentation of Cantargia’s report for the first half of 2023 on August 22 at 3.00 p.m. CEST
Jun 4, 2023
Cantargia publishes ASCO 2023 poster on promising nadunolimab efficacy in non-small cell lung cancer
May 23, 2023
(R) Annual General Meeting in Cantargia AB (publ)
May 9, 2023
Invitation to presentation of Cantargia’s report for the first quarter of 2023 on May 23 at 10.00 a.m. CEST
Apr 20, 2023
(R) Cantargia has submitted a phase I clinical trial application for its second project, CAN10
Apr 19, 2023
(R) Cantargia presents anti-metastatic effects of nadunolimab in cancer models at AACR 2023
Apr 4, 2023
Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023
Mar 14, 2023
(R) Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer
Mar 14, 2023
(R) Cantargia treats first triple-negative breast cancer patient in randomized phase II part of TRIFOUR trial
Feb 23, 2023
(R) Cantargia publishes full year report for 2022
Feb 14, 2023
Invitation to presentation of Cantargia’s Year-end report of 2022 on February 23 at 3.00 p.m. CET
Jan 13, 2023
